This Medical Technology Leader Sees Growth Into The 2040s | Investor's Business DailySPECIAL REPORT: [Find The Online Broker That Best Fits Your Needs]---Medical technology leader Halozyme Therapeutics (HALO) is this week's IBD Sector Leaders selection, having bypassed two buy points and entered a buy zone. The recent IBD Stock Of The Day is rallying after the company raised its 2025 and 2026 outlook. It also offered a bold forecast for 2027, 2028 and beyond. The biopharmaceutical company's enzyme technolog ...

Core Viewpoint - The article emphasizes the importance of investing in high-quality growth and momentum stocks that are reasonably priced, with a focus on long-term performance and potential market outperformance [1] Group 1: Investment Strategy - The investment strategy involves focusing on growth and momentum stocks that are expected to outperform the market over the long term [1] - The analyst has a history of advising investors to buy at market lows, specifically citing a recommendation in March 2009 during the financial crisis, which led to significant market gains [1] Group 2: Market Performance - From 2009 to 2019, the S&P 500 saw an increase of 367%, while the Nasdaq experienced a remarkable increase of 685%, highlighting the potential for substantial returns in the stock market [1]

Halozyme, IBD Stock Of The Day, Near Buy Point; Why It's A Story Of 'Layering And Duration' | Investor's Business DailyBREAKING: [Futures Mixed: AMD, Lumentum Lead Earnings Latel----Halozyme Therapeutics Halozyme Therapeutics HALO $ 75.36 $0.91 1.22% 15% IBD Stock Analysis Stock with 74.2.5 double bottom buy point HALO investors should probably use 75.59 handle entry Composite Rating 99/99 Industry Group Ranking 8/197 Emerging Pattern Double Bottom Double Bottom One of the three positive chart patterns to l ...

Core Insights - The article highlights several stocks that are trading near buy points, with a focus on companies benefiting from data center expansion [1] Group 1: Stocks to Watch - GE Vernova (GEV) has successfully broken out past a buy point [1] - Vertiv Holdings (VRT), Dycom Industries (DY), Halozyme Therapeutics (HALO), and Viking Holdings (VIK) are also identified as stocks to watch, trading near buy points [1] - Among these, GE Vernova, Vertiv, and Dycom have reported a 35% growth in earnings per share, indicating strong performance linked to data center expansion [1] Group 2: Market Context - The article notes that the U.S. government is entering a shutdown, which may impact market conditions [1] - Despite market fluctuations, certain stocks like GE Vernova and others are highlighted for their potential as they approach key levels [1]

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the 11 Best Stocks to Buy for Investment. On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C. Wainwright remains positive on HALO, considering the strategic and financial strength of its ENHANZE platform. Kapoor believes the recent business developments with Takeda and Skye are a significant win for the company, expanding ENHANZE’s reach beyond ...

Core Insights - Halozyme Therapeutics (HALO) shares increased nearly 4% after the release of preliminary full-year 2025 results that exceeded expectations, along with an upward revision of sales and EPS guidance for 2026 [1][6]. Financial Performance - Preliminary revenues for full-year 2025 are projected to be between $1.39 billion and $1.40 billion, reflecting a year-over-year growth of 36% to 38%, surpassing previous guidance of $1.30 billion to $1.38 billion and the Zacks Consensus Estimate of $1.35 billion [4]. - Anticipated royalty revenues for 2025 are expected to be in the range of $865 million to $870 million, indicating a year-over-year growth of 51% to 52% [5]. 2026 Guidance - For 2026, total revenues are expected to be between $1.71 billion and $1.81 billion, representing a growth of 23% to 30% over projected 2025 revenues [6]. - Royalty revenues for 2026 are now anticipated to be between $1.13 billion and $1.17 billion, implying a year-over-year growth of 30% to 35%, ahead of previous expectations of $900 million to $940 million [7]. - Adjusted earnings per share for 2026 are projected to be between $7.75 and $8.25, an increase from earlier projections of $6.50 to $7.00 [8]. Strategic Developments - The raised guidance for adjusted EBITDA and earnings per share includes a financial impact of approximately $60 million from the acquisition of Hypercon and Surf Bio technologies, which were not included in earlier guidance [9]. - By the end of 2026, the company expects to have 15 partner programs in development and aims to sign three or more new drug-delivery licensing agreements [10]. Market Performance - Over the past year, shares of Halozyme have increased by 29.1%, compared to the industry growth of 15.6% [2].

PresentationGood morning. My name is Eric, and I will be your conference operator today. At this time, I would like to welcome everyone to Halozyme's Investor Conference Call. [Operator Instructions] Please note, this event is being recorded.Tram BuiHead of Investor Relations & Corporate Communications Thank you, operator. Good morning, and welcome to Halozyme's investor conference call. In addition to the press release issued earlier this morning, you can find a supplementary slide presentation that will b ...

For smaller-volume, at-home administration, Halozyme highlighted Hypercon and Surf Bio, which management said can enable hyperconcentration of therapeutics up to approximately 500 mg/mL—potentially reducing injection volumes to less than 2 mL or into a 2 mL to 10 mL range that could fit either a small-volume autoinjector or Halozyme’s proprietary high-volume autoinjector.Torley also pointed to two areas of emerging interest for ENHANZE: potential applications with nucleic acids (including interest in lipid ...

Halozyme Therapeutics (NasdaqGS:HALO) Update / briefing January 28, 2026 08:30 AM ET Company ParticipantsBrendan Smith - DirectorCorinne Johnson - Managing DirectorDavid Risinger - Senior Managing DirectorHelen Torley - President and CEOJason Butler - Managing DirectorMichael DiFiore - Managing DirectorMohit Bansal - Managing DirectorNicole LaBrosse - CFOConference Call ParticipantsMitchell Kapoor - Director and Senior Biotechnology AnalystOperatorGood morning. My name is Eric, and I will be your conference ...

Revenue Projections - Halozyme expects total revenue for 2025 to be between $1,385 million and $1,400 million, representing a year-over-year growth of 36% to 38%[1] - Royalty revenue for 2025 is projected to be between $865 million and $870 million, with a year-over-year growth of 51% to 52%[1] - For 2026, total revenue guidance has been raised to between $1,710 million and $1,810 million, indicating a year-over-year growth of 23% to 30%[1] - Royalty revenue for 2026 is expected to be between $1,130 million and $1,170 million, reflecting a growth of 30% to 35% compared to 2025[1] Financial Metrics - Adjusted EBITDA for 2026 is projected to be between $1,125 million and $1,205 million, including a new investment of approximately $60 million[1] - Non-GAAP diluted EPS for 2026 is expected to be between $7.75 and $8.25[1] Acquisitions and Collaborations - The company acquired Surf Bio for an upfront payment of $300 million, with potential milestone payments of up to $100 million, totaling up to $400 million[5] - The acquisition of Surf Bio enhances Halozyme's drug delivery portfolio with innovative hyperconcentration technology, enabling high concentrations of therapeutics[6] - In 2025, Halozyme signed three new ENHANZE collaboration agreements and advanced its strategic growth roadmap with acquisitions[4] - By the end of 2026, Halozyme anticipates having 15 partner programs in development and signing three or more new drug delivery licensing agreements[5] - The company is focusing on expanded collaborations and potential approvals of new partnered or proprietary products[21] Risks and Uncertainties - There are uncertainties regarding future market conditions and competitive environments that could impact actual results[21] - The expected benefits from acquisitions of Elektrofi and Surf Bio are under evaluation[21] - The company acknowledges potential risks related to patent terms for drug delivery technologies[21] - There may be unexpected levels of revenues, expenditures, and costs affecting business growth[21] - Delays in the development, regulatory review, or commercialization of products could occur[21] - Regulatory approval requirements are a significant factor in the company's future outlook[21] - The company does not undertake any duty to update forward-looking statements after the release date[21]